OncoImmunology (Dec 2024)

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes

  • Joel Kidman,
  • Rachael M. Zemek,
  • John-William Sidhom,
  • Debora Correa,
  • Nicola Principe,
  • Fezaan Sheikh,
  • Vanessa S. Fear,
  • Catherine A. Forbes,
  • Abha Chopra,
  • Louis Boon,
  • Ayham Zaitouny,
  • Emma de Jong,
  • Robert A. Holt,
  • Matt Jones,
  • Michael J. Millward,
  • Timo Lassmann,
  • Alistair R.R. Forrest,
  • Anna K. Nowak,
  • Mark Watson,
  • Richard A. Lake,
  • W. Joost Lesterhuis,
  • Jonathan Chee

DOI
https://doi.org/10.1080/2162402X.2024.2345859
Journal volume & issue
Vol. 13, no. 1

Abstract

Read online

ABSTRACTImmune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. Using murine models that exclude variation in host genetics, environmental factors and tumour mutation burden, limiting variation between animals to naturally diverse TCRβ repertoires, we applied TCRseq, single cell RNAseq and flow cytometry to study TCRβ repertoire dynamics in ICT responders and non-responders. Increased oligoclonal expansion of TCRβ clonotypes was observed in responding tumours. Machine learning identified TCRβ CDR3 signatures unique to each tumour model, and signatures associated with ICT response at various timepoints before or during ICT. Clonally expanded CD8+ T cells in responding tumours post ICT displayed effector T cell gene signatures and phenotype. An early burst of clonal expansion during ICT is associated with response, and we report unique dynamics in TCRβ signatures associated with ICT response.

Keywords